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Abstract
Background: Lethal mutagenesis, or virus extinction promoted by mutagen-induced elevation of mutation rates of viruses,
may meet with the problem of selection of mutagen-resistant variants, as extensively documented for standard, non-
mutagenic antiviral inhibitors. Previously, we characterized a mutant of foot-and-mouth disease virus that included in its
RNA-dependent RNA polymerase replacement M296I that decreased the sensitivity of the virus to the mutagenic nucleoside
analogue ribavirin.
Methodology and Principal Findings: Replacement M296I in the viral polymerase impedes the extinction of the mutant
foot-and-mouth disease virus by elevated concentrations of ribavirin. In contrast, wild type virus was extinguished by the
same ribavirin treatment and, interestingly, no mutants resistant to ribavirin were selected from the wild type populations.
Decreases of infectivity and viral load of the ribavirin-resistant M296I mutant were attained with a combination of the
mutagen 5-fluorouracil and the non-mutagenic inhibitor guanidine hydrocloride. However, extinction was achieved with a
sequential treatment, first with ribavirin, and then with a minimal dose of 5-fluorouracil in combination with guanidine
hydrochloride. Both, wild type and ribavirin-resistant mutant M296I exhibited equal sensitivity to this combination,
indicating that replacement M296I in the polymerase did not confer a significant cross-resistance to 5-fluorouracil. We
discuss these results in relation to antiviral designs based on lethal mutagenesis.
Conclusions: (i) When dominant in the population, a mutation that confers partial resistance to a mutagenic agent can
jeopardize virus extinction by elevated doses of the same mutagen. (ii) A wild type virus, subjected to identical high
mutagenic treatment, need not select a mutagen-resistant variant, and the population can be extinguished. (iii) Extinction
of the mutagen-resistant variant can be achieved by a sequential treatment of a high dose of the same mutagen, followed
by a combination of another mutagen with an antiviral inhibitor.
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Introduction
RNA virus genomes do not replicate as a defined nucleotide
sequence, but as complex and dynamic mutant spectra termed
viral quasispecies (reviews in [1,2]). Quasispecies dynamics is the
result of high mutability, and constitutes a major factor in the
adaptability of RNA viruses to changing environments. From a
practical point of view, adaptability represents a challenge for the
design of effective treatments to control diseases associated with
highly variable viruses [3–10]. In particular, viral mutants resistant
to antiviral inhibitors are systematically selected both in experi-
mental settings and in clinical practice. New antiviral strategies are
now under investigation to avoid or minimize selection of drug-
resistant virus mutants, and the ensuing treatment failure. One
such strategies is termed lethal mutagenesis, that aims at
extinguishing virus through an increase of the virus mutation
rate, above the maximum level compatible with virus viability
[2,11–14]. An important development in lethal mutagenesis was
the discovery that the nucleoside analogue ribavirin [1-(b-D-
ribofuranosyl)-1H-1,2,4-triazole-3-carboxamide] (R), currently li-
censed as an antiviral agent, is mutagenic for poliovirus [15–17]. A
mutagenic activity of R was subsequently reported for other
viruses, including foot-and-mouth disease virus (FMDV) and
hepatitis C virus (HCV) [18–25]. R has several mechanisms of
action [26,27], and a relevant, still unsettled question is whether R
acts as a mutagenic agent in the course of treatment of HCV-
infected patients, when R is administered in combination with
IFN-a [28–33].
A critical issue in a lethal mutagenesis approach to treat viral
infections is whether mutagen-resistant mutants can be selected,
and whether they can jeopardize treatment efficacy. R-resistant
mutants of several RNA viruses have been selected and
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characterized [34–38]. A poliovirus (PV) mutant resistant to R
included replacement G64S in its RNA-dependent RNA poly-
merase (RdRp, termed 3D), and this replacement increased
template-copying fidelity, and rendered PV less adaptable to a
complex environment, relative to the wild type virus [39–43].
Despite the PV and foot-and-mouth disease virus (FMDV)
polymerases being closely related structurally [44], a FMDV
mutant with decreased sensitivity to R included replacement
M296I in its 3D, a site distant from that where the PV substitution
G64S is located. The FMDV mutant is termed M296I, and,
contrary to substitution G64S in PV, M296I increased modestly
the ARG transition frequency relative to wild type 3D, and
restricted specifically the incorporation of R-triphosphate (RTP)
during RNA elongation [37,45]. The comparison of PV mutant
G64S and FMDV mutant M296I has documented that different
sites in the picornavirus polymerase can modulate incorporation of
nucleotide analogues, and that R-resistance does not require a
general increase of template-copying fidelity of the polymerase
[45]. Lethal mutagenesis of FMDV has been studied in our
laboratory, with regard to the effect of viral load and viral fitness
on extinction [46], changes in population complexity associated
with extinction [18,47], and the advantages of a combination of a
mutagen and antiviral inhibitors over a mutagen alone as a
treatment to achieve virus extinction in cell culture [48,49]. The
effect of substitution M296I in 3D on FMDV extinction has not
been studied.
Here we report that FMDV mutant M296I, with no other
mutations in its genome, is not extinguished upon passage in the
presence of high R concentrations. In contrast, the wild type (WT)
virus was extinguished under the same treatment and passage
conditions, and no R-resistant mutants were selected under high R
concentrations. However, extinction of FMDV M296I was
achieved by treatment with another mutagen (5-fluorouracil,
FU), in combination with an inhibitor of viral replication
[guanidine hydrochloride, GU [49–51]]. Implications for antiviral
designs based on lethal mutagenesis are discussed.
Results
Replacement M296I in 3D can prevent FMDV extinction
by high ribavirin concentrations
Serial cytolytic passages of FMDV in the presence of increasing
concentrations of R (200 mM and up to 800 mM) resulted in
selection of a FMDV mutant harboring amino acid substitution
M296I in the polymerase (3D) [37]. The mutant FMDV displayed
higher replicative fitness than the wild type FMDV in the presence
of R, but lower fitness in the absence of R. In polymerization
assays in vitro, the mutant 3D showed decreased capacity to use
RTP as substrate (in the place of GTP and ATP) than wild type
3D [37,45]. To investigate whether substitution M296I in 3D
could jeopardize the extinction of FMDV by ribavirin treatment,
virus that differed only at amino acid residue 296 in 3D were
expressed from plasmids pMT28-WT, and pMT28-M296I,
respectively. Throughout the present report, these two progeny
viruses are abbreviated as WT and M296I, respectively. FMDV
WT and M296I were subjected to serial cytolytic passages in
BHK-21 cells in the presence or absence of a high concentration
(5 mM) of R. FMDV WT was extinguished by passage 6,
according to the criteria for virus extinction (absence of infectivity
and of virus-specific genetic material), detailed in Materials and
Methods (Fig. 1A). In contrast, FMDV M296I was not
extinguished, and, beginning at passage 3, the virus increased
progressively its replication rate (Fig. 1B). The evolution of
infectivity paralleled that of viral RNA level (viral load), and the
specific infectivity in the presence and absence of R remained
constant form passage 4 until at least passage 10. The mutant
population that increased its replication in the presence of R
(Fig. 1B) was analyzed by comparing the consensus nucleotide
(and deduced amino acid sequence) of the entire viral genome at
passages 2, 5, 8 and 10. The results (Table 1) show an increase in
the number of mutations that reached 14 (4 nonsynonymous and
10 synonymous, of which 2 were not dominant in the consensus) at
passage 10. This represents a rate of accumulation of mutations of
1.5 per passage, a rate 6- to 15-fold higher than estimated for large
population passages of FMDV in the absence of R [52,53] (p,
0.005; x2 test; calculated from the number of mutations in large
populations passages in the absence and presence of R). GRA and
CRU transitions, those induced by R [37,45], amounted to 50%
of the total (Table 1). Substitution M296I in 3D was maintained,
and additional nonsynomymous mutations in VP3, 2C, 3A and
3D became dominant. Because these mutations are likely to confer
a selective advantage to the virus in the presence of R, they are
currently under study. Although the presence of substitution
M296I in 3D at the onset of R treatment prevented extinction of
FMDV during cytolytic infections, this mutation was not selected
when FMDV WT clone was subjected to treatment with high R
concentrations, and FMDV WT was extinguished.
Extinction of FMDV M296I by a combination of 5-
fluorouracil and guanidine hydrochloride requires
exceeding a minimal mutagenic activity
Since the presence of 3D replacement M296I in FMDV
permitted the virus to escape extinction, it was interesting to
investigate whether extinction could be achieved by treatment
with a different mutagenic agent. Because of previous work with
FMDV, FU was the mutagen of choice [46,48,49,54]. However,
FU alone was not sufficient to achieve systematic FMDV
extinction [46,48], and, therefore, a combination of FU
(200 mg/ml) and GU (4 mM) (termed combination FUG-200)
was used [48]. The effect of FUG-200 was tested with FMDV WT
and mutant M296I at different passages, and for M296I it was
tested also following treatment with R (5 mM). In all cases, the
FUG-200 treatment led to a several orders of magnitude decrease
in viral infectivity and viral load, that reached values below or
close to the limits of detection (Fig. 2). Despite such sharp
decreases, FMDV-specific RT-PCR amplifiable material was
detected in all cases in the supernatant of the treated, infected
cells. A very minor (but still visible) amplification band was
discerned in samples of M296I replicated in the presence of R, and
then treated with FUG (compare bottom panels in Fig. 2). Thus,
despite dramatic decreases of infectivity and viral load, FMDV
WT and M296I could not be considered extinguished, according
to our criteria of extinction (described in Materials and Methods).
FU levels of 100 to 2000 mg/ml do not adversely affect viability
of BHK-21 cells under the conditions used for FMDV infection
(80% viable cells after 36 h exposure to 2000 mg/ml FU [46]). To
test whether increased mutagenic activity could drive FMDV WT
and M296I to extinction, we tested a FUG combination with
500 mg/ml FU instead of 200 mg/ml FU, and 4 mM GU, using
an identical experimental design as that used with 200 mg/ml FU.
This new FUG combination is termed FUG-500. In this case, all
populations (except FMDV WT at passage 10) reached infectivity
levels below the limit of detection (Fig. 3). The RT-PCR
amplification of samples of cell culture supernatants provided
amplification bands with minimal intensity for FMDV WT and
M296I subjected to FUG-500 treatment, confirming the drastic
effect that the treatment had on viral load. Interestingly, no DNA
amplification band was detected in the supernatant of cultures
Ribavirin-Resistant Mutant
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infected with M296I in the presence of R for 2, 5 and 8 passages,
and then with the FUG-500 combination (compare bottom panels
in Fig. 3). To further ascertain extinction, the cells from the
cultures that did not show FMDV infectivity and RNA following
the FUG-500 treatment, were passaged in the absence of any
drug. No infectivity or FMDV RNA were detected in cell culture
supernatants, following the extinction test described in Materials
and Methods. In contrast to extinction by FUG-500 of the
populations passaged 2, 5 and 8 times in the presence of R, no
extinction was achieved in the case of the population passaged 10
times in the presence of R (Fig. 3C). Absence of extinction in this
case was probably due to the passage history in the presence of R,
and to the high fitness attained by M296I after 10 passages in the
presence of R [55,56].
Therefore, a sequential treatment of a FMDV mutant that
harbors a R-resistance mutation in its polymerase, first with high
R concentrations, and then with a combination of an unrelated
mutagen and an inhibitor of viral replication, can result in virus
extinction.
Passage history influences extinction
FMDV M296I passaged in the presence of R had a history of R
mutagenesis prior to FUG-500 treatment. Since viral load affects
extinction [46], we studied the effect of FUG-500 on M296I,
without the counfounding effects of virus passage in the presence
of R. To this aim unpassaged FMDV M296I was adjusted to a
number of plaque-forming-units (PFU)/ml comprised between
1.56102 and 5.56105 which correspond to the range of titers
attained by M296I in the presence of R (Fig. 3C). In parallel we
also tested FMDV WT with the same range of initial titers. When
these unpassaged WT and M296I populations were subjected to
FUG-500, extinction was observed in all cases, as evidenced by
loss of FMDV infectivity, absence of FMDV RNA, and absence of
FMDV-specific RT-PCR amplifiable sequences (Fig. 4). There-
fore, passage in BHK-21 cells in the presence of R contributed to
extinction-escape of FMDV M296I.
Extinction-escape is prompted by guanidine-resistance
mutations in FMDV
In previous studies on extinction of FMDV by FU and FU-GU
combinations, extinction failure was associated with selection of
GU-resistant mutants harboring amino acid replacements in non-
structural protein 2C [49]. To investigate whether GU-resistance
mutations were selected in FMDV WT or M296I populations
subjected to 5 passages under FUG-200 or FUG-500, the 2C-
coding region was sequenced. Some RNAs were not analyzed
because of insufficient amount of material amplified by RT-PCR;
they correspond to viral populations that attained very low
Figure 1. Absence of extinction of FMDVM296I after treatment
with ribavirin. BHK-21 cells (26106 cells) were initially infected with
the indicated viruses (WT, wild type FMDV; M296I, FMDV with
substitution M296I in 3D) at a multiplicity of infection (MOI) of about
0.3 PFU/cell. In succesive passages, the same number of cells were
infected with the supernatant from the previous passage. Viruses and
the absence or presence of ribavirin (R) (5 mM) are indicated in the
boxes at the top of panels A and B; (A) Infectivity of FMDV WT in the cell
culture supernatants. Values are the mean6SD (error bars) of triplicate
determinations. The discontinuous line indicates the limit of detection
of FMDV infectivity. (B) Infectivity, viral RNA levels and specific
infectivity in the supernatants of BHK-21 cells infected with FMDV
M296I. Titrations and quantifications of FMDV RNA were carried out in
triplicate; standard deviations are given. Viral RNA was extracted and
quantified by real time PCR. The discontinuous lines indicate the limit of
detection of infectivity and viral RNA. Values of specific infectivity
(PFUs/RNA molecules) were calculated from the infectivities and viral
RNA levels given in the two previous panels of (B). Procedures for
titration of virus infectivity and quantification of FMDV RNA, as well as
the positive and negative controls included in the assays, are described
in Materials and Methods.
doi:10.1371/journal.pone.0005554.g001
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infectivity and viral RNA levels. The results (Tables 2 and 3)
indicate that in all populations subjected to FUG-200 or FUG-
500, whose RNA could be amplified, mutations that were
previously associated with GU-resistance were present, either
alone or with additional mutations (Tables 2 and 3). In particular,
substitutions K169R and C141S in 2C, which were dominant in
several populations, confer GU resistance in FMDV [49,50].
I248N was found in 3 populations and, although this substitution
had not been previously identified in FMDV populations, I248T
was frequently associated with GU resistance [49]. For several
populations the region around the nucleotide encoding M296 of
3D was sequenced. For mutant M296I, this substitution was
maintained upon FUG treatment, as expected.
In conclusion, the comparative analysis of FMDV WT and
mutant M296I populations subjected to R and FU mutagenesis
indicates that the presence of a mutagen-resistance mutation can
impede viral extinction by increased doses of the same mutagen.
Subsequent treatment with a different mutagen-inhibitor combi-
nation can lead to virus extinction.
Discussion
Selection of inhibitor-resistant viral mutants is a consequence of
quasispecies dynamics, and an important problem in antiviral
therapy. When highly variable RNA viruses attain large viral loads
in infected patients, combination therapy with at least 3 inhibitors
that target different steps in the virus life cycle has been recognised
as a means to prevent or delay selection of inhibitor-resistant
mutants. The benefits of combination therapy to counteract
quasispecies adaptability have been supported by both, theoretical
studies on virus population dynamics, and clinical observations
([57–63], among other studies). Mutation frequencies among
components of viral quasispecies in vivo are such that mutations
that confer resistance to antiviral agents are often represented in
patients not subjected to therapy with the relevant inhibitors. This
includes patients who could not have been infected by a virus
harboring the corresponding resistance mutation [64–68].
Lethal mutagenesis of viruses has opened prospects for an
alternative antiviral strategy consisting in the use of mutagenic
agents specific for virus polymerases, with the objective of driving
viruses across an extinction threshold [2,11,13,14,16,17,69,70].
Experimental, theoretical and in silico studies, suggest that one of
the molecular mechanisms that contribute to virus extinction by
lethal mutagenesis is interference by a subclass of mutant viral
genomes, termed defectors [71–73]. According to this model,
interference by defectors generated under enhanced mutagenesis is
added to the increased proportion of genomes with lethal
mutations that favor extinction through a reduction of viral load
[46]. With these underlying influences, it is not clear what the
effect of a mutation that decreases partially the sensitivity to a
mutagenic agent would be regarding extinction.
The evidence that R is mutagenic for FMDV includes (i)
increase of mutation frequency of mutant spectra of populations
passaged in the presence of R, and a dominance of CRU and
GRA transitions, relative to populations passaged in the absence
of R [18,37]; (ii) selection of a FMDV mutant that encodes
substitution M296I in the viral polymerase (3D) in populations
passaged in the presence of increasing concentrations of R, but not
in populations passaged in parallel but in the absence of R [37].
Replacement M296I in 3D has not been detected in mutant
spectra from FMDV populations not subjected to mutagenesis, or
subjected to mutagenesis by FU or 5-azacytidine or subjected to
Table 1. Mutations in FMDV M296I passaged in the presence of ribavirin.
Genomic regionb Passage 2 Passage 5 Passage 8 Passage 10
Mutationc Amino acidc Mutationc Amino acidc Mutationc Amino acidc Mutationc Amino acidc
59 UTR A809G - A809G -
59 UTR U986C - U986C - U986C -
L U1044C - U1044C -
VP2 C2379U/C -
C2625U/C -
VP3 A3112G I188V A3112G I188V
C3144U - C3144U -
VP1 U3699C - U3699C -
2B A4131C - A4131C - A4131C -
C4134C/U C4134U -
2C C4748U T135I C4748U T135I
3A G5602A D102N G5602A D102N
3C C6540U - C6540U -
C6588U - C6588U -
3D A7396G T263A A7396G T263A
C7605U/C - C7605U/C -
aThe sequence of the entire viral genome was determined for FMDV M296I after 2, 5, 8 and 10 passages in the presence of 5 mM ribavirin. The populations are those
described in Fig. 1B. Mutation and deduced amino acid substitutions are relative to the sequence of the parental clone FMDV M296I.
bFMDV genomic region analyzed; residue numbering is according to [74].
cMutations and deduced amino acid substitutions found. Amino acid residues (single-letter code) are numbered individually for each protein from the N- to the C-
terminus. Boldface type indicates a change in the amino acid residue. Two residues separated by a bar indicate a mixture of two nucleotides in the population,
according to the sequence band pattern. Procedures for nucleotide sequencing and identification of FMDV genomic regions are described in Materials and Methods.
doi:10.1371/journal.pone.0005554.t001
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plaque-to-plaque transfers [46,48,49,53,74–76] (iii) FMDV en-
coding M296I in 3D displayed increased fitness relative to the wild
type virus in the presence of R but not in its absence [37]. (iv) In
assays carried out with purified 3D in vitro, the enzyme with
M296I showed decreased incorporation of RTP oposite C or U in
the template, relative to the wild type enzyme. These results
indicate that R is mutagenic for FMDV, that substitution M296I
was selected specifically upon replication of FMDV in the presence
of R, and that M296I conferred a selective advantage to the virus
when replicating in the presence of R but not in its absence. Both,
virological and biochemical analyses did not provide any evidence
that M296I increased the fidelity of the viral polymerase. In fact, a
modest decrease in copying fidelity was observed. The reason why
FMDV mutant in not extinguished by R is probably that
substitution M296I specifically decreases the incorporation of
RMP during RNA synthesis [37,45]. The modest decrease in
fidelity in unlikely to provide a number of defectors genomes
sufficient to outweigh the decrease of defector genomes due to R-
mediated mutagenesis during replication of the mutant virus.
The mechanism by which M296I in 3D of FMDV confers
resistance to R is different from the mechanism by which substitution
G64S of PV3D exerts its resistance. M296I is located at the b9-a11
loop of FMDV 3D which is critical for nucleotide recognition at the
active site of the enzyme [77,78]. This substitution specifically
decreases the capacity of the enzyme to use RTP as substrate. In
contrast, G64S in 3D of PV is away from the catalytic site of the
polymerase and, through distant interactions, it increases the
copying fidelity of the polymerase [39–42]. These studies with
mutant 3D of FMDV and PV indicate that picornaviruses have at
least two mechanisms to render the virus less sensitive to ribavirin: (i)
a general increase of fidelity that decreases incorporation of incorrect
nucleotides, and (ii) a change that specifically decreases the
incorporation of RTP (reviewed in [79]).
FMDV is about 10-fold more sensitive to R in the course of
persistent infections than during cytolytic infectious in the same
BHK-21 cells [18,80]. This permits sustained replication of
cytolytic FMDV over several passages in the presence of elevated
concentrations of R, thus allowing evaluation of the effects of
Figure 2. Response of FMDV wild type and mutant M296I to 5-fluorouracil-guanidine combination treatment. FMDV wild type (WT) or
mutant M296I were serially passaged in the absence or presence of R (5 mM), as described in the legend for Fig. 1, and as indicated in the boxes at
the top. At passages 2, 5, 8 and 10, the viral populations were subjected to additional passages in the presence of a combination of 5-fluorouracil (FU,
200 mg/ml) and guanidinium hydrochloride (GU, 4 mM) (combination FUG-200); p indicates passage number, either in the absence of any drug
(panels A and B), or in the presence of 5 mM R (panel C), prior to the FUG-200 treatment. Virus titers and amounts of FMDV RNA in the cell culture
supernatants were determined at each passage, as indicated in each panel. Discontinuous lines indicate the limit of detection of infectivity or FMDV
RNA. Titrations and quantifications of FMDV were carried out in triplicate; standard deviations are given. Viral RNA was amplified by RT-PCR as a test
for virus extinction, as described in Materials and Methods [bottom panels: M, molecular size markers (Hind III-digested Ø29 DNA; fragment size in
base pairs is indicated on the right); C2, negative control, amplification without RNA; C+, positive RT-PCR amplification control, M, C2 and C+ were
run for each analysis in A, B, C, but included here in A for simplicity]. Procedures for drug treatments, titration of infectivity, quantification of FMDV
RNA by real time PCR, and for RT-PCR amplification are detailed in Materials and Methods.
doi:10.1371/journal.pone.0005554.g002
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genetic and environmental conditions on the kinetics of extinction.
As described in Materials and Methods, the presence of 5 mM R
for 31 hours in BHK-21 cell monolayers under the conditions
used for infections with FMDV, allowed survival of 40% to 50% of
cells. Therefore, toxicity for cells was not the reason for FMDV
extinction, as further supported by survival and increased
replication of FMDV mutant M296I upon passage in the presence
of 5 mM R (Fig. 1B).
In the present report we have addressed this question by
investigating whether a mutation that decreases sensitivity of
FMDV to R can impede extinction of the virus in the course of
cytolytic passages of the virus. The results have shown that
replication of M296I and WT FMDV follow different trajectories
when replicating in the presence of 5 mM R, and replacement
M296I prevented virus extinction. Interestingly, however, in the
course of passage of FMDV WT in the presence of 5 mM R, no
mutant with M296I in 3D became dominant, and the virus was
extinguished (Fig. 1). It must be emphasized that the initial WT
and mutant viruses differed exclusively in substitution M296I since
they were reconstructed from infectious plasmids, as described in
Materials and Methods. New mutations arise continuously upon
FMDV replication in cell culture both in the absence and the
presence of R [18,37,46,81]. The requirement of initially low and
then gradually increasing R concentrations to select for mutant
M296I [37], and the failure to select the same mutant by
subjecting the same virus to 5 mM R, may relate to suppressive
effects of the FMDV quasispecies when populated by higher
frequencies of mutant genomes generated under elevated
mutagenic intensities [71,73]. An alternative, not mutually
exclusive possibility, is that as the multiplicity of infection (MOI)
decreases with the passage number, a potential R-resistant mutant
that is generated with low frequency is excluded from the following
passage. Experiments are in progress to test these possibilities. Two
conclusions can be derived from these experiments: (i) once
established as dominant in a viral population, a mutagen-resistant
mutation can prevent viral extinction by high doses of the same
mutagenic agent; (ii) a wild type virus need not select a mutagen-
resistance mutation, when replicating under high concentrations of
the mutagen, and, therefore, extinction may occur.
As an approach to drive FMDV mutant M296I towards
extinction we studied the fate of WT and mutant populations
subjected to mutagenesis with a combination of FU and GU. We
had previously established that a combination of FU and GU was
more efficient than FU alone in driving FMDV towards extinction
[48,49]. Therefore, we chose to use the FUG combination as a
means to extinguish M296I, the latter either with or without a
history of R mutagenesis. In the two FUG regimes tested (with
either 200 mg/ml or 500 mg/ml FU), the treatment was successful
Figure 3. Response of FMDV wild type and mutant M296I to 5-fluorouracil-guanidine treatment, with increased mutagen dose. The
experimental design, symbols, drugs, procedures and controls are the same as described in the legend for Fig. 2, except that the FU concentration
used was 500 mg/ml FU [FU (500 mg/ml) and GU (4 mM), abbreviated as FUG-500 in the boxes on the top]. Note the absence of infectivity and of an
RT-PCR amplification band upon replication of M296I first in the presence of R (5 mM) (2 to 8 passages, but not 10 passages), followed by treatment
with FU-500. Extinction of M296I (panel C) was further ascertained by the absence of infectivity or RT-PCR amplifiable viral materials, after three
passages of the cells that harbored the putatively extinguished FMDV, in the absence of any drug, as justified in Materials and Methods. Titrations and
quantifications of FMDV were carried out in triplicate; standard deviations are given.
doi:10.1371/journal.pone.0005554.g003
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Figure 4. Response of FMDV wild type and mutant M296I to 5-fluorouracil-guanidine combination treatment. Unpassaged FMDV wild
type (WT) or mutant M296I was adjusted to a number of PFU/ml comprised between 5.56105 and 1.56102 which correspond to the maximum titer
(passage 10 in Fig. 3C) and the minimum titer (passage 2 in Fig. 3C) attained by M296I in the presence of R. Subsequently, populations were
Ribavirin-Resistant Mutant
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in that very low or undetectable infectivity and viral load of WT
and M296I FMDV were achieved. There was no evidence that the
presence of mutation M296I impaired the antiviral activity of
FUG (compare panels A and B in Figs. 2 and 3). Yet, when a more
stringent extinction criterion was used (absence of viral genetic
material amplifiable by RT-PCR), extinction was ascertained only
for M296I treated with R and then with FUG (with 500 mg/ml
FU, not with 200 mg/ml FU) (compare panels C of Figs. 2 and 3).
Therefore, extinction of M296I was favored by prior R
mutagenesis, and a minimum mutagenic dose by FU was required
for extinction. Extinction failure was associated with the presence
of GU-resistant replacements in 2C. This results confirms and
extends previous observations [49], and alerts of the problem to
render an inhibitor inefficient when administered together with a
mutagen that enhances the mutation rate.
We cannot exclude that treatment with a combination of the
two mutagens FU and R could also result in virus extinction, and
these experiments are now in progress. Here, important
considerations are toxicity effects derived from the administration
of two mutagens, their doses, and confounding effects that might
ensue from the simultaneous action of two mutagenic agents that
tend to produce opposite mutation types (mainly GRA and CRU
by R, versus mainly ARG and URC by FU [18,37,45,46,54]).
Preliminary experiments show that passage of mutant M296I in
the presence of FU alone tends to revert this substitution since
reversion depends on a ARG transition, a type of mutation
favored by FU treatment [37,54] (M. Sierra and E. Domingo,
unpublished results). Thus, R and FU exert opposed selective
pressures regarding the genetic stability of mutant M296I. Also,
most mutations that have been associated with resistance of
FMDV to GU are ARG transitions, and they could have been
favored by the presence of FU in the FUG combination.
Concerning the interpretation of our results and a possible
clinical application of lethal mutagenesis, the effects of FU and R
on the host cells and organisms must be taken into consideration.
FU derivatives can act as inhibitors of enzymes involved in
Table 2. Mutations in FMDV populations subjected to mutagenesis (FUG-200 combination).
FMDV populationa
Region analyzed (genomic
residues)b RT-PCR amplificationc Mutationd
Amino acid
substitutiond
WT p2 2C (4345–5299) + A4850G K169R
WT p5 2C (4325–5325) 2 N. A. N. A.
WT p8 2C (4325–5325) + A4850G K169R
WT p10 2C (4326–5308) + A4597G I85V
A4850G K169R
M296I p2 2C (4325–5325) 2 N. A. N. A.
M296I p5 2C (4325–5325) + U4765A C141S
U5087C I248N
M296I p8 2C (4327–5299) + A4744A/G R134R/G
A4850A/G K169K/R
U5087U/C I248I/N
M296I p10 2C (4325–5325) + A4850G K169R
U5087C I248N
M296I+R p2 2C (4345–5299) 2 N. A. N. A.
M296I+R p5 2C (4345–5299) 2 N. A. N. A.
M296I+R p8 2C (4345–5299) 2 N. A. N. A.
M296I+R p10 2C (4345–5299) 2 N. A. N. A.
aThe populations correspond to those described in Figure 2 [either WT or M296I subjected to 2, 5, 8 or 10 passages in absence or presence of R 5 mM] and then, in all
cases, subjected to 5 passages in the presence of [FU(200 mg/ml)+GU (4 mM); FUG-200 combination]; +R means that passages were carried out in the presence of
5 mM ribavirin.
bThe FMDV genomic region analyzed. In all cases, the region that was sequenced spanned the entire 2C-coding region; residue numbering is according to [74].
cIt indicates whether the RT-PCR amplification of the genomic region given in the second column produced sufficient DNA for sequencing (+) or not (2). The primers
used for the RT-PCR amplification, and the conditions for amplification are detailed in Materials and Methods.
dMutations and deduced amino acid substitutions found. Two residues separated by a bar indicate a mixture of two nucleotides (and deduced amino acids) in the
population, according to the sequencing band pattern. N.A. means not analyzed. Procedures for nucleotide sequencing and identification of FMDV genomic regions
are described in Materials and Methods.
doi:10.1371/journal.pone.0005554.t002
subjected to passages in the presence of 5-fluorouracil (FU, 500 mg/ml) and guanidinium hydrochloride (GU, 4 mM) (combination FUG-500). The virus
(WT, panel A; M296I, panel B) and drug treatment are indicated in the boxes at the top; ‘p2’, ‘p5’, ‘p8’ and ‘p10’ indicate that the number of initial PFU/
ml of FMDV WT and M296I was adjusted to the same titer attained by M296I in the presence of R at passage 2, 5, 8 and 10, respectively (data of
Fig. 3C). Virus titers and amounts of FMDV RNA in the cell culture supernatants were determined at each passage, as indicated in each panel;
titrations and quantifications of FMDV were carried out in triplicate; standard deviations (not given) never exceeded 30% of the mean. Viral RNA was
amplified by RT-PCR as a test for virus extinction, as described in Materials and Methods [bottom panels: M, molecular size markers (Hind III-digested
Ø29 DNA; fragment size in base pairs is indicated on the right); C2, negative control, amplification without RNA; C+, positive RT-PCR amplification
control, M, C2 and C+ were run for each analysis in A and, B, but included here only in A for simplicity]. Procedures for drug treatments, titration of
infectivity, quantification of FMDV RNA by real time PCR, and for RT-PCR amplification are detailed in Materials and Methods.
doi:10.1371/journal.pone.0005554.g004
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nucleotide metabolism, and can be incorporated into DNA and all
forms of RNA, affecting gene expression ([18,48,49,82,83],
reviewed in [18]). R can have several effects on nucleotide
metabolism, and as immunomodulator [26,27,84]. Ribavirin
monophosphate (RMP) is a competitive inhibitor of inosine
monophosphate dehydrogenase (IMPDH) thereby lowering the
levels of intracellular GTP. Such reduction can contribute to some
mutagenic activity due to imbalances in the ribonucleotide pool
concentrations [18]. As a G analogue, R can inhibit m-RNA
capping and the activity of RNA polymerases [85]. In a
microarray-based study of the effect of R on epithelial cells
infected with respiratory syncytial virus, R potentiated the virus-
induced IFN-stimulated response element (ISRE) that enhances
the expression of antiviral response genes stimulated by IFN [86].
These effects of R suggest a mechanism to explain the efficacy of a
combination treatment involving R and IFN-a in chronic viral
infections, such as HCV infections [86,87]. Thus, the current
evidence is that R exerts its antiviral activity through a number of
alternative and not mutually exclusive mechanisms. These
multiple influences on the host will require an adequate dosing
of FU and R as antiviral agents, and careful consideration of
possible inhibitors to be included in the formulations.
Estimates of the R concentration reached in vivo during antiviral
treatments are of 600–800 mM at the site of infection after aerosol
administration, and maximum serum or cerebrospinal fluid
concentrations of 20–150 mM after intravenous or oral adminis-
tration ([88–90]; reviewed in [18]). These concentrations are lower
than those used in our model studies. Extinction as a direct result
of the treatment, which in our experiments has been taken as the
most strict test of antiviral efficacy, may not be necessary to clear
virus in vivo. A decrease in viral load may be sufficient to give an
opportunity to the immune system to clear the virus. Also, early
inititation of treatment, before a virus increases its fitness in the
infected organism, will be more effective to reduce the viral load
and to eliminates the virus.
In conclusion, FMDV populations doomed to extinction failure
because of the dominance of a mutagen-resistant mutation, could
still be driven towards extinction by a combination treatment
involving another mutagen and a non-mutagenic antiviral
inhibitor. We are currently planning the exploration of this lethal
mutagenesis protocol in vivo, using a mouse model for FMDV, a
system previously used to document that the mutant spectrum
composition of the viral quasispecies plays an essential role in
virulence [91]. Possible lethal mutagenesis protocols suggested by
the present study avoid the simultaneous administration of two
mutagenic gents, thereby minimizing toxicity for cells or
organisms.
Materials and Methods
Cells and viruses
The origin of BHK-21 cells and procedures for cell growth in
Dulbecco’s modification of Eagle’s medium (DMEM), and for
plaque assays in semisolid agar have been previously described
[81,92]. To control for the absence of contamination, supernatants
of mock-infected cells were titrated in parallel; no signs of
infectivity or cytopathology in the cultures or in the control plaque
assays were observed in any of the experiments.
Mutagenic treatments
A solution of ribavirin (R) in PBS was prepared at a
concentration of 100 mM, sterilized by filtration, and stored at
270uC. Prior to use, the stock solution was diluted in DMEM to
reach the desired R concentrations. For infections in the presence
of R, cell monolayers were treated during 7 h with 5 mM R prior
to infection. After adsorption of FMDV and washing of the cell
Table 3. Mutations in FMDV populations subjected to mutagenesis (FUG-500 combination).
FMDV populationa
Region analyzedb
(genomic residues) RT-PCR amplificationc Mutationd Amino acid substitutiond
WT p2 2C (4328–5323) + A4850G K169R
WT p5 2C (4345–5323) + A4850G K169R
WT p8 2C (4345–5323) + A4850G K169R
WT p10 2C (4331–5319) + A4597G I85V
A4850G K169R
M296I p2 2C (4345–5311) + A4850G K169R
M296I p5 2C (4327–5323) + A4850G K169R
M296I p8 2C (4327–5322) + A4850G K169R
M296I p10 2C (4345–5299) 2 N. A. N. A.
M296I+R p2 2C (4345–5299) 2 (RNA extinct) N. A. N. A.
M296I+R p5 2C (4345–5299) 2 (RNA extinct) N. A. N. A.
M296I+R p8 2C (4345–5299) 2 (RNA extinct) N. A. N. A.
M296I+R p10 2C (4345–5322) + No mutations No substitutions
aThe populations correspond to those described in Figure 2 [either WT or M296I subjected to 2, 6, 8 or 10 passages in absence or presence of R 5 mM] and then, in all
cases, subjected to 5 passages in the presence of [FU (500 mg/ml) + GU (4 mM); FUG-500 combination]; +R means that passages were carried out in the presence of
5 mM ribavirin.
bThe FMDV genomic region analyzed. In all cases, the region that was sequenced spanned the entire 2C-coding region; residue numbering is according to [74].
cIt indicates whether the RT-PCR amplification of the genomic region given in the second column produced sufficient DNA for sequencing (+) or not (2). The primers
used for the RT-PCR amplification, and the conditions for amplification are detailed in Materials and Methods.
dMutations and deduced amino acid substitutions found. N.A. means not analyzed. Procedures for nucleotide sequencing and identification of FMDV genomic regions
are described in Materials and Methods.
doi:10.1371/journal.pone.0005554.t003
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monolayers, the infection was allowed to proceed in the presence
of same concentration of R. FMDV C-S8c1 was passaged serially
in the absence or in the presence of R (5 mM). For each passage
26106 BHK-21 cells were infected with supernatant of virus from
the previous passage (0.2 ml), and the infection allowed to proceed
for about 24 h. In each passage carried out in the absence of R,
26106 BHK-21 cells were infected with 9.86106–1.46106 PFU of
WT or mutant M296I. In the presence of R, 26106 BHK-21 cells
were infected with 2.16104–2.26102 PFU (first passage) and
56102 PFU down to 1 PFU (for WT populations that reach very
low infectivity). Values for each passage can be estimated from the
infectivities given in Figure 1. Infections in the absence of R, and
mock-infected cells, were maintained in parallel; no evidence of
contamination of cells with virus was observed at any time.
Incubation of confluent BHK-21 cells monolayers (as used for
infections with FMDV) with 5 mM R for 31 hours resulted in cell
viabilities of 40% to 50%, as determined with trypan blue
exclusion (range calculated in six different determinations).
Therefore, toxicity of R for the cells cannot account for FMDV
extinction (see also Discussion).
To prepare culture medium containing 5-fluorouracil (FU)
(Sigma), the analogue was dissolved in DMEM to yield a 5 mg/ml
solution, and diluted in DMEM, as needed for the experiments.
To prepare medium containing guanidine (GU) (Sigma), a solution
of GU in DMEM was prepared at a concentration of 50 mM. To
prepare medium containing a mixture of both FU and GU, the
appropriate amount of GU was added to DMEM containing FU
to yield solutions containing either FU (200 mg/ml) and GU
(4 mM), termed FUG-200, or FUG (500 mg/ml) and GU (4 mM),
termed FUG-500. All solutions were sterilized by filtration.
Precautions to ensure stability of the drug preparations prior to
use, and measurements of toxicity for BHK-21 cells, and have
been previously described [18,46].
For infections in the presence of FU and GU, confluent cell
monolayers were pretreated for 13 h with 200 mg/ml or 500 mg/
ml FU. After virus adsorption, the infections were allowed to
proceed in the presence of FUG-200 or FUG-500 for approx-
imately 24 h. The inhibition of infectious progeny production
associated with the different treatments described in the present
study, in a standard FMDV infection at a MOI of 1–2 PFU/cell
was: 99.7% for treatment with 5 mM R, and 99.9% for treatment
with the FUG-200 or FUG-500 combinations. For serial passage
of virus, 0.2 ml of cell supernatant from the previous infection was
used to infect a cell monolayer (26106 BHK-21 cells) pretreated
with FU as described above. In the course of treatment with FUG-
200 or FUG-500 of viruses not exposed to R, 26106 BHK-21 cells
were infected with 56106–96106 PFU (first passage) and 26103–
56103 down to 1 PFU (for populations that reach very low
infectivity). For M296I treated with R, 26106 BHK-21 cells were
infected with 1.16105–1.56102 PFU (first passage) and 6.26102
down to 1 PFU (for populations that reach very low infectivity).
Values for each passage can be estimated from the infectivities
given in Figures 2 and 3. No FMDV extinction occurs in serial
viral passages carried out at very low MOI in the absence of
mutagens [48,49]. Virus was titrated after each passage. All
titrations were carried out in triplicate, and standard deviations
calculated, as indicated in the corresponding experiments. Mock-
infected cells were maintained in parallel; no evidence of
contamination of cells with virus was observed at any time.
RNA extraction, RNA quantification, cDNA synthesis and
PCR amplification
Viral RNA was extracted from the medium of infected cultures
using Trizol (Invitrogen) as previously described [53]. Reverse
transcription was performed with AMV reverse transcriptase
(Promega), and PCR amplification was carried out using Expand
High Fidelity (Roche), as specified by the manufacturers. The 2C-
coding region was amplified using as primers oligonucleotides
2BR2 (59-GAAGACCTTGAGAGAGCAG; sense orientation; the
59 nucleotide corresponds to genomic residue 4318), and 2CD4
(59- ACACAGATTTTTGGGAAGGT; antisense orientation; the
59 nucleotide corresponds to genomic residue 5326). The 3D-
coding region was amplified using two sets of primers. One set
included oligonucleotides A2SacI (59-CACACATCGACCCT-
GAACCGCACCACGA; sense orientation; the 59 nucleotide
corresponds to genomic residue 6581), and AV4 (59-
TTCTCTTTTCTCCATGAGCTT; antisense orientation; the
59 nucleotide corresponds to genomic residue 7071). The second
set included oligonucleotides 3DR1 (59- GAAACGCCGCGGTG-
CACTTATC; sense orientation; the 59 nucleotide corresponds to
genomic residue 6984), and ED6 (59-AATCATTGTGC-
CAATTGTGAT; antisense orientation; the 59 nucleotide corre-
sponds to genomic residue 8053). Genomic residues are numbered
as described in [74]. Amplification products were analyzed by
agarose gel electrophoresis using Hind III-digested Ø-29 DNA as
molar mass standards. Negative controls (amplifications in the
absence of RNA) were included in parallel to ascertain absence of
contamination by template nucleic acids. No evidence of
contamination with extraneous templates was obtained in any of
the experiments reported here.
Assessment of FMDV extinction
FMDV was considered extinct when no virus infectivity and no
viral RNA that could be amplified by a highly sensitive RT-PCR
protocol, could be demonstrated neither in the supernatant of the
passage that harbors the putatively extinguished virus, nor after 3
blind passages in BHK-21 cells, in the absence of any drug. Multiple
highly sensitive RT-PCR amplification reactions that yield short
cDNAs were carried out to ascertain extinction. These criteria to
consider FMDV extinct [18,37,46,48,49] have now been extended
to show that no infectivity or RT-PCR amplifiable material can be
retrieved after three passages of the cells that harbor the putatively
extinguished virus. This extension was prompted by the observation
that FMDV subjected to hundreds of plaque-to-plaque transfers
could lose capacity to form plaques and yet maintain intracellular
RNA [53]. It should be noted the loss of infectivity below the level of
detection did not necessarily imply extinction of viral genetic
material (compare Figs. 2 and 3 in Results).
Quantification of FMDV RNA
Real time quantitative RT-PCR was carried out using the Light
Cycler RNA Master SYBR Green I kit (Roche), according to the
instructions of the manufacturer, as described previously for
FMDV RNA [53]. The 2C-coding region was amplified using as
primers oligonucleotides 2CR2 (59- GGCAAACCCTTCAG-
CAGTAAG; sense orientation; the 59 nucleotide corresponds to
genomic residue 4924), and 2CD3 (59- CGCTCACGTC-
GATGTCAAAGTG; antisense orientation; the 59 nucleotide
corresponds to genomic residue 5047). Quantification was relative
to a standard curve obtained with known amounts of FMDV
RNA, synthesized by in vitro transcription of FMDV cDNA
(plasmid pMT28, described in [93]). The specificity of the reaction
was monitored by determining the denaturation curve of the
amplified DNAs. Negative controls (without template RNA, or
with RNA from mock-infected cells) were run in parallel with each
amplification reaction. Again, no evidence of contamination with
extraneous templates was obtained in any of the experiments
reported here.
Ribavirin-Resistant Mutant
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